2016
DOI: 10.1016/j.ejso.2016.08.001
|View full text |Cite
|
Sign up to set email alerts
|

Does the addition of oxaliplatin to preoperative chemoradiation benefit cT4 or fixed cT3 rectal cancer treatment? A subgroup analysis from a prospective study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
13
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 14 publications
(13 citation statements)
references
References 16 publications
0
13
0
Order By: Relevance
“…All 14 RCTs reported the rate of pCR. The chemoradiation regimen in the study of Wiśniowska et al13 included short-term radiotherapy (5×5 Gy irradiation over 5 days) combined with consolidation chemotherapy and long-course chemoradiation (50.4 Gy in 28 fractions of 1.8 Gy given concomitantly with chemotherapy). Only the data regarding long-course chemoradiation were extracted for the present meta-analysis to minimize heterogeneity.…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…All 14 RCTs reported the rate of pCR. The chemoradiation regimen in the study of Wiśniowska et al13 included short-term radiotherapy (5×5 Gy irradiation over 5 days) combined with consolidation chemotherapy and long-course chemoradiation (50.4 Gy in 28 fractions of 1.8 Gy given concomitantly with chemotherapy). Only the data regarding long-course chemoradiation were extracted for the present meta-analysis to minimize heterogeneity.…”
Section: Resultsmentioning
confidence: 99%
“…For the analysis of sensitivity, the RCTs of low quality were removed. Either the study in which true randomization was unclear was excluded,13 or two studies in which the 5FU schedule varied between two arms were excluded 21,22. For the rate of pCR, there was no evidence of inconsistency, and the results of the NMA did not significantly change after removing these articles.…”
Section: Resultsmentioning
confidence: 99%
“…Long-course radiation was used in most studies but the dose was a little lower in an individual early study (34.5 Gy) (25). In the aspect of surgical intervention, some articles did not mention it (11)(12)(13)(14)(15)(16)20,21,27,29,30,32). Moreover, the rest of the studies reported the interval to be 3-10 weeks.…”
Section: Discussionmentioning
confidence: 99%
“…In spite of this, researchers are still exploring, but most clinical studies have shown that the addition of Oxa not only does not help to improve the pCR rate of patients [23][24][25][26], but also significantly increases the incidence of therapeutic toxicity such as bone marrow suppression and diarrhea [23,25,26]. In contrast, a meta-analysis of three large samples from 2017 to 2019 showed that although regimens using Oxa can expose patients to greater therapeutic toxicity, it is, however, beneficial for the short/long-term effect of patients [27][28][29].…”
Section: Oxaliplatinmentioning
confidence: 99%
“…At present, there is a large amount of evidence determining the efficacy of bevacizumab in the systematic treatment of colorectal cancer patients, but its application in nCRT for LARC patients is still being explored. Existing research [60][61][62][63][64][65][66] shows that adding bevacizumab to the Fu-nCRT regimen can achieve a pCR rate of 16-36% for LARC patients, compared to the 12%-34% obtained by Oxa+Fu-nCRT regimen [14][15][16][17][18][19][23][24][25][26], and is numerically superior to the 11%-15% achieved by the independent Fu-nCRT regimen [9,10]. In the phase II study of Xiao et al [67], 25 patients with LARC were treated with sandwich-like neoadjuvant therapy, that is, bevacizumab combined with FOLFOX induction + Fu-nCRT + sequential FOLFOX.…”
Section: Bevacizumabmentioning
confidence: 99%